MX2024002238A - Anticuerpos anti-ccr8 y uso de los mismos. - Google Patents
Anticuerpos anti-ccr8 y uso de los mismos.Info
- Publication number
- MX2024002238A MX2024002238A MX2024002238A MX2024002238A MX2024002238A MX 2024002238 A MX2024002238 A MX 2024002238A MX 2024002238 A MX2024002238 A MX 2024002238A MX 2024002238 A MX2024002238 A MX 2024002238A MX 2024002238 A MX2024002238 A MX 2024002238A
- Authority
- MX
- Mexico
- Prior art keywords
- antigen
- ccr8 antibodies
- binding fragments
- ccr8
- antibodies
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
- C07K2317/41—Glycosylation, sialylation, or fucosylation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/715—Assays involving receptors, cell surface antigens or cell surface determinants for cytokines; for lymphokines; for interferons
- G01N2333/7158—Assays involving receptors, cell surface antigens or cell surface determinants for cytokines; for lymphokines; for interferons for chemokines
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Biomedical Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Veterinary Medicine (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Food Science & Technology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2021113913 | 2021-08-20 | ||
| PCT/CN2022/113739 WO2023020621A1 (en) | 2021-08-20 | 2022-08-19 | Anti-ccr8 antibodies and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2024002238A true MX2024002238A (es) | 2024-04-29 |
Family
ID=85239303
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2024002238A MX2024002238A (es) | 2021-08-20 | 2022-08-19 | Anticuerpos anti-ccr8 y uso de los mismos. |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20250019451A1 (https=) |
| EP (1) | EP4388009A4 (https=) |
| JP (1) | JP2024531409A (https=) |
| KR (1) | KR20240046533A (https=) |
| CN (1) | CN118176210A (https=) |
| AU (1) | AU2022331786A1 (https=) |
| CA (1) | CA3225986A1 (https=) |
| IL (1) | IL310938A (https=) |
| MX (1) | MX2024002238A (https=) |
| WO (1) | WO2023020621A1 (https=) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI890283B (zh) | 2020-02-14 | 2025-07-11 | 美商基利科學股份有限公司 | 結合ccr8之抗體及融合蛋白及其用途 |
| WO2024040216A2 (en) | 2022-08-19 | 2024-02-22 | Fibrogen, Inc. | Anti-ccr8 antibodies and uses thereof |
| JP2025534340A (ja) * | 2022-10-02 | 2025-10-15 | アールイーエムディー バイオセラピューティクス，インコーポレイテッド | Ｃ－ｃケモカイン受容体タイプ８（ｃｃｒ８）アンタゴニスト抗体 |
| JPWO2024248037A1 (https=) | 2023-05-30 | 2024-12-05 | ||
| WO2024255753A1 (zh) * | 2023-06-12 | 2024-12-19 | 南京蓬勃生物科技有限公司 | 结合人ccr8的抗体及其用途 |
| WO2025011439A1 (zh) * | 2023-07-07 | 2025-01-16 | 齐鲁制药有限公司 | 一种抗人ccr8的单克隆抗体药物制剂及其用途 |
| TW202540200A (zh) | 2023-12-01 | 2025-10-16 | 美商基利科學股份有限公司 | 抗ｆａｐ－ｌｉｇｈｔ融合蛋白及其用途 |
| WO2025145207A1 (en) | 2023-12-29 | 2025-07-03 | Bristol-Myers Squibb Company | Combination therapy of kras inhibitor and treg-depleting agent |
| WO2025259871A1 (en) | 2024-06-14 | 2025-12-18 | Gilead Sciences, Inc. | Anti-ccr8 antibodies and uses thereof |
| CN119371535B (zh) * | 2024-09-20 | 2025-07-11 | 百济神州(上海)生物科技有限公司 | 抗ccr8抗体及其用途 |
| CN119841954B (zh) * | 2025-03-12 | 2025-11-04 | 上海百英生物科技股份有限公司 | 一种抗人ccr8单克隆抗体及其制备方法 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2007044756A2 (en) * | 2005-10-11 | 2007-04-19 | Icos Corporation | Monoclonal antibodies recognizing human ccr8 |
| WO2020138489A1 (ja) * | 2018-12-27 | 2020-07-02 | 塩野義製薬株式会社 | 新規抗ｃｃｒ８抗体 |
| CA3160204A1 (en) * | 2020-01-06 | 2021-07-15 | Vaccinex, Inc. | Anti-ccr8 antibodies and uses thereof |
| TWI890283B (zh) * | 2020-02-14 | 2025-07-11 | 美商基利科學股份有限公司 | 結合ccr8之抗體及融合蛋白及其用途 |
| TW202216771A (zh) * | 2020-06-26 | 2022-05-01 | 德商拜耳廠股份有限公司 | 用於治療應用之ccr8抗體 |
-
2022
- 2022-08-19 KR KR1020247007534A patent/KR20240046533A/ko active Pending
- 2022-08-19 CA CA3225986A patent/CA3225986A1/en active Pending
- 2022-08-19 AU AU2022331786A patent/AU2022331786A1/en active Pending
- 2022-08-19 JP JP2024510434A patent/JP2024531409A/ja active Pending
- 2022-08-19 MX MX2024002238A patent/MX2024002238A/es unknown
- 2022-08-19 WO PCT/CN2022/113739 patent/WO2023020621A1/en not_active Ceased
- 2022-08-19 CN CN202280069781.2A patent/CN118176210A/zh active Pending
- 2022-08-19 US US18/685,068 patent/US20250019451A1/en active Pending
- 2022-08-19 EP EP22857930.6A patent/EP4388009A4/en active Pending
- 2022-08-19 IL IL310938A patent/IL310938A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CN118176210A (zh) | 2024-06-11 |
| JP2024531409A (ja) | 2024-08-29 |
| WO2023020621A1 (en) | 2023-02-23 |
| EP4388009A1 (en) | 2024-06-26 |
| EP4388009A4 (en) | 2025-07-09 |
| US20250019451A1 (en) | 2025-01-16 |
| KR20240046533A (ko) | 2024-04-09 |
| CA3225986A1 (en) | 2023-02-23 |
| AU2022331786A1 (en) | 2024-04-04 |
| IL310938A (en) | 2024-04-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2024002238A (es) | Anticuerpos anti-ccr8 y uso de los mismos. | |
| PH12020552010A1 (en) | Anti-cd33 antibodies, anti-cd33/anti-cd3 bispecific antibodies and uses thereof | |
| ZA202311412B (en) | Anti-phf-tau antibodies and uses thereof | |
| ZA202004730B (en) | Anti-claudin 18.2 antibodies and uses thereof | |
| ZA202006318B (en) | Anti-dll3 antibodies and uses thereof | |
| PH12020550214A1 (en) | Antibodies specific to cd47 and pd-l1 | |
| PH12021552790A1 (en) | Materials and methods for modulating t cell mediated immunity | |
| MX2023014458A (es) | Anticuerpos anti-ccr8 y usos de los mismos. | |
| SA519402358B1 (ar) | Ccr7 مترافقات عقار جسم مضاد لـ | |
| MX2022010664A (es) | Materiales y métodos para modular una respuesta inmunitaria. | |
| PH12022553035A1 (en) | Anti-phf-tau antibodies and uses thereof | |
| NZ789630A (en) | Anti-lilrb1 antibody and uses thereof | |
| ZA202302392B (en) | Antibodies against ilt2 and use thereof | |
| MX2023002948A (es) | Métodos y composiciones para modular la inmunidad mediada por cadena beta. | |
| MX2022015966A (es) | Anticuerpos y metodos para tratar enfermedades asociadas a claudina. | |
| MX2023011340A (es) | Anticuerpos humanizados contra el filamento helicoidal emparejado tau y usos de estos. | |
| MX2021015766A (es) | Nuevos antigenos y metodos contra el cancer. | |
| MX2021004454A (es) | Anticuerpos anti-sinucleina. | |
| MX2023011339A (es) | Anticuerpos anti-tau y usos de estos. | |
| MX2022007513A (es) | Anticuerpos biespecificos con cisteinas intercatenarias apareadas alternativamente y sus usos. | |
| MX2024011805A (es) | Nuevos anticuerpos anti-fgfr2 | |
| MX2023009211A (es) | Anticuerpos biespecificos con pares de carga y usos de los mismos. | |
| MX2022013920A (es) | Anticuerpos anti-antigeno asociado con tumor y usos de los mismos. | |
| AU2018345715A8 (en) | DNA monoclonal antibodies targeting CTLA-4 for the treatment and prevention of cancer | |
| MX2024009326A (es) | Anticuerpos anti-btla y usos de los mismos en el tratamiento del cancer. |